Posted by Michael Wonder on 14 Sep 2019
Right to try ‘remains a bust,’ as many drug makers prefer FDA reviews
12 September 2019 - Despite the hubbub over the “right-to-try” law, a recent survey found that nearly half of drug makers indicated they would require regulators to review a decision to provide an experimental treatment to a person with a life-threatening disease.
Specifically, 13 of 29 drug companies indicated they want a relevant regulatory authority to review requests that are granted to such people.
Of these, six specified they would ask the FDA to conduct a review and five stated they require a research ethics committee or institutional review board, according to a report from the Government Accountability Office.
